The company based in Massachusetts(MA)reported a risein revenue to $292.60 milion for the year when compared to $213.58 million in the previous year.
A filing from the company with the Securities and Exchange Commission on Mar 10,2023 showed that its revenue is up 37.00% year-over-year.
The company reported basic earnings per share of $182782680 and diluted earnings per share of $182782680.
Akebia Therapeutics, Inc. operates in the Pharmaceutical Preparations sector.
Related News